Pfizer disputes suit claiming Zoloft doesn't work

by The Associated Press

(AP)—The maker of Zoloft is being sued in an unusual case alleging the popular antidepressant has no more benefit than a dummy pill. The federal lawsuit, filed in California, argues that patients who took it should be reimbursed for their costs.

Zoloft's maker, ., disagrees. It says clinical studies and the experience of millions of patients and their doctors over two decades prove Zoloft is effective.

Pfizer and four psychiatry experts interviewed by The Associated Press call the lawsuit frivolous.

But the plaintiff, Laura Plumlee, says Zoloft didn't help her during three years of treatment. Her attorney, R. Brent Wisner, argues the shouldn't have approved Zoloft because Pfizer didn't publish some studies that found the drug about as effective as a placebo.

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Pfizer anti-smoking drug has heart risks: US

Jun 16, 2011

US regulators said Thursday that the label on Pfizer's anti-smoking drug Chantix must be changed to warn of a slightly higher risk of heart problems in patients who already have cardiovascular disease.

FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

FDA panel backs Pfizer drug for kidney cancer

Dec 07, 2011

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

Citing liver damage, Pfizer withdraws Thelin

Dec 10, 2010

(AP) -- Pfizer Inc. said Friday it is pulling its blood pressure drug Thelin off the market and stopping all clinical trials because the drug can cause fatal liver damage.

FDA clears Pfizer drug for advanced kidney cancer

Jan 27, 2012

(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.